Literature DB >> 17640656

Simultaneous quantification of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid in human plasma using two-dimensional gas chromatography, cryofocusing, and electron impact-mass spectrometry.

Ross H Lowe1, Erin L Karschner, Eugene W Schwilke, Allan J Barnes, Marilyn A Huestis.   

Abstract

A two-dimensional (2D) gas chromatography/electron impact-mass spectrometry (GC/EI-MS) method for simultaneous quantification of Delta(9)-tetrahydrocannabinol (THC), 11-hydroxy-Delta(9)-tetrahydrocannabinol (11-OH-THC), and 11-nor-Delta(9)-tetrahydrocannabinol-9-carboxylic acid (THCCOOH) in human plasma was developed and validated. The method employs 2D capillary GC and cryofocusing for enhanced resolution and sensitivity. THC, 11-OH-THC, and THCCOOH were extracted by precipitation with acetonitrile followed by solid-phase extraction. GC separation of trimethylsilyl derivatives of analytes was accomplished with two capillary columns in series coupled via a pneumatic Deans switch system. Detection and quantification were accomplished with a bench-top single quadrupole mass spectrometer operated in electron impact-selected ion monitoring mode. Limits of quantification (LOQ) were 0.125, 0.25 and 0.125 ng/mL for THC, 11-OH-THC, and THCCOOH, respectively. Accuracy ranged from 86.0 to 113.0% for all analytes. Intra- and inter-assay precision, as percent relative standard deviation, was less than 14.1% for THC, 11-OH-THC, and THCCOOH. The method was successfully applied to quantification of THC and its 11-OH-THC and THCCOOH metabolites in plasma specimens following controlled administration of THC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17640656      PMCID: PMC2714866          DOI: 10.1016/j.chroma.2007.06.069

Source DB:  PubMed          Journal:  J Chromatogr A        ISSN: 0021-9673            Impact factor:   4.759


  31 in total

Review 1.  Investigating the neurocognitive deficits associated with chronic drug misuse.

Authors:  R D Rogers; T W Robbins
Journal:  Curr Opin Neurobiol       Date:  2001-04       Impact factor: 6.627

Review 2.  Adverse effects of cannabis and cannabinoids.

Authors:  C H Ashton
Journal:  Br J Anaesth       Date:  1999-10       Impact factor: 9.166

3.  The determination of 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) in hair using negative ion gas chromatography-mass spectrometry and high-volume injection.

Authors:  C Moore; F Guzaldo; T Donahue
Journal:  J Anal Toxicol       Date:  2001-10       Impact factor: 3.367

Review 4.  Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use.

Authors:  Frank Musshoff; Burkhard Madea
Journal:  Ther Drug Monit       Date:  2006-04       Impact factor: 3.681

5.  Application of two-dimensional gas chromatography with electron capture chemical ionization mass spectrometry to the detection of 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) in hair.

Authors:  Christine Moore; Sumandeep Rana; Cynthia Coulter; Fred Feyerherm; Harry Prest
Journal:  J Anal Toxicol       Date:  2006-04       Impact factor: 3.367

6.  The detection of Delta9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol (THCA) in whole blood using two-dimensional gas chromatography and EI-mass spectrometry.

Authors:  Rodger D Scurlock; Greg B Ohlson; David K Worthen
Journal:  J Anal Toxicol       Date:  2006-05       Impact factor: 3.367

7.  Estimating time of last oral ingestion of cannabis from plasma THC and THCCOOH concentrations.

Authors:  Marilyn A Huestis; Mahmoud Elsohly; Wesenyalsh Nebro; Allan Barnes; Richard A Gustafson; Michael L Smith
Journal:  Ther Drug Monit       Date:  2006-08       Impact factor: 3.681

8.  Simultaneous determination of delta9-tetrahydrocannabinol and 11-nor-9-carboxy-delta9-tetrahydrocannabinol in human plasma by solid-phase extraction and gas chromatography-negative ion chemical ionization-mass spectrometry.

Authors:  W Huang; D E Moody; D M Andrenyak; E K Smith; R L Foltz; M A Huestis; J F Newton
Journal:  J Anal Toxicol       Date:  2001-10       Impact factor: 3.367

9.  Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis.

Authors:  D T Wade; P M Makela; H House; C Bateman; P Robson
Journal:  Mult Scler       Date:  2006-10       Impact factor: 6.312

10.  Marijuana use is associated with a reorganized visual-attention network and cerebellar hypoactivation.

Authors:  L Chang; R Yakupov; C Cloak; T Ernst
Journal:  Brain       Date:  2006-04-03       Impact factor: 13.501

View more
  32 in total

1.  Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings.

Authors:  Jose M Trigo; Dina Lagzdins; Jürgen Rehm; Peter Selby; Islam Gamaleddin; Benedikt Fischer; Allan J Barnes; Marilyn A Huestis; Bernard Le Foll
Journal:  Drug Alcohol Depend       Date:  2016-02-23       Impact factor: 4.492

2.  Determination of ∆-9-Tetrahydrocannabinol (THC), 11-hydroxy-THC, 11-nor-9-carboxy-THC and Cannabidiol in Human Plasma using Gas Chromatography-Tandem Mass Spectrometry.

Authors:  David M Andrenyak; David E Moody; Matthew H Slawson; Daniel S O'Leary; Margaret Haney
Journal:  J Anal Toxicol       Date:  2017-05-01       Impact factor: 3.367

3.  Antagonist-elicited cannabis withdrawal in humans.

Authors:  David A Gorelick; Robert S Goodwin; Eugene Schwilke; David M Schwope; William D Darwin; Deanna L Kelly; Robert P McMahon; Fang Liu; Catherine Ortemann-Renon; Denis Bonnet; Marilyn A Huestis
Journal:  J Clin Psychopharmacol       Date:  2011-10       Impact factor: 3.153

4.  Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry.

Authors:  Garry Milman; Allan J Barnes; Ross H Lowe; Marilyn A Huestis
Journal:  J Chromatogr A       Date:  2010-01-04       Impact factor: 4.759

5.  Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC.

Authors:  Eugene W Schwilke; David M Schwope; Erin L Karschner; Ross H Lowe; William D Darwin; Deanna L Kelly; Robert S Goodwin; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2009-10-15       Impact factor: 8.327

6.  Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws.

Authors:  Mateus M Bergamaschi; Erin L Karschner; Robert S Goodwin; Karl B Scheidweiler; Jussi Hirvonen; Regina H C Queiroz; Marilyn A Huestis
Journal:  Clin Chem       Date:  2013-03       Impact factor: 8.327

7.  Tolerance to effects of high-dose oral δ9-tetrahydrocannabinol and plasma cannabinoid concentrations in male daily cannabis smokers.

Authors:  David A Gorelick; Robert S Goodwin; Eugene Schwilke; David M Schwope; William D Darwin; Deanna L Kelly; Robert P McMahon; Fang Liu; Catherine Ortemann-Renon; Denis Bonnet; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2012-10-16       Impact factor: 3.367

8.  Impact of oral fluid collection device on cannabinoid stability following smoked cannabis.

Authors:  Sébastien Anizan; Mateus M Bergamaschi; Allan J Barnes; Garry Milman; Nathalie Desrosiers; Dayong Lee; David A Gorelick; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2014-07-03       Impact factor: 3.345

Review 9.  Addictions Neuroclinical Assessment: A reverse translational approach.

Authors:  Laura E Kwako; Reza Momenan; Erica N Grodin; Raye Z Litten; George F Koob; David Goldman
Journal:  Neuropharmacology       Date:  2017-03-07       Impact factor: 5.250

10.  Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers.

Authors:  Erin L Karschner; Eugene W Schwilke; Ross H Lowe; W David Darwin; Ronald I Herning; Jean Lud Cadet; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2009-10       Impact factor: 3.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.